Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14752728 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL26178758 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL8737682 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL4553865 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL16436993 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL28923405 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL25319217 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL7106115 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL14877952 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 | |
| SCHEMBL4721611 | 1.00 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101559053-A | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-10-21 | — | — | CN | claimed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| CN-112494656-B | Insulin receptor partial agonists | 默沙东有限责任公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | THE WISTAR INST (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-100488506-C | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-05-20 | — | — | CN | disclosed |
| US-7468460-B2 | Reacting benzhydroxamic acid with benzyl alcohol and 2,4,6- substituted 1,3,5,2,4,6-trioxatriphosphinane in presence of triethylamine to produce benzyloxycarbonylaniline | ARCHIMICA GMBH (DE) | 2008-12-23 | — | — | US | disclosed |
| US-20080221357-A1 | Method for Producing Amines from Hydroxamic Acids | EUTICALS GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1904433-A1 | METHOD FOR PRODUCING AMINES FROM HYDROXAMIC ACIDS | Archimica GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| US-7199145-B2 | Derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D' 'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2007-04-03 | — | — | US | disclosed |
| WO-2007006465-A1 | METHOD FOR PRODUCING AMINES FROM HYDROXAMIC ACIDS | ARCHIMICA GMBH (DE) | 2007-01-18 | — | — | WO | disclosed |
| CN-1391474-A | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | disclosed |
| US-4089865-A | Certain thiazole compounds | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | HSPA2, HSPBP1, HSP90AB1 | TDP1 893/4885EPHX1 2174/4885MAOA 3656/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | TDP1 2488/4885EPHX1 3694/4885MAOA 3413/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | TDP1 2942/4885EPHX1 3695/4885MAOA 4018/4885 |
| US-20080221357-A1 | Method for Producing Amines from Hydroxamic Acids | HRH3, HCAR2, HAO2 | TDP1 3396/4885EPHX1 1209/4885MAOA 156/4885 |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | MCTS1, CA14, TTL | TDP1 3825/4885EPHX1 2323/4885MAOA 3680/4885 |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | KCNH1, CACNA1B, CACNA1C | TDP1 3626/4885EPHX1 1633/4885MAOA 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.